Background: Extracorporeal membrane oxygenation (ECMO) is administered for a few days after lung transplantation (LTx) in recipients who are expected to have early graft dysfunction. Despite its life-saving potential, immediate postoperative ECMO has lifethreatening complications such as postoperative bleeding. We investigated the risk factors related to the use of immediate postoperative ECMO. Methods: We retrospectively reviewed the records of 60 LTx patients who were at our institution from October 2012 to May 2015. Perioperative variables associated with postoperative ECMO were compared between the two groups. Results: There were 26 patients who received postoperative ECMO (ECMO group) and 34 patients who did not (control group). Multivariate regression analysis revealed preoperative ECMO (odds ratio [OR] 12.55, 95% confidence intervals [CI] 1.34 -117.24, p = 0.027) and lower peripheral pulse oxymetry saturation (SpO 2 ) at the end of surgery (OR 0.71, 95% CI 0.54 -0.95, p = 0.019) were independent risk factors for postoperative ECMO in LTx patients. The incidences of complications, such as re-operation, tracheostomy, renal failure and postoperative atrial fibrillation, were higher in the ECMO group. There was no difference in the duration of postoperative intensive care unit stay or postoperative 30-day mortality between the two groups.
Introduction
Over the past decades, lung transplantation has become an important therapeutic option for end-stage lung diseases. [1] In 1963, the first lung transplantation in humans was attempted by Dr. James Hardy at the University of Mississippi, and the recipient survived only 18 days. Since then, many advances have been made to improve outcomes and the International Society for Heart and Lung Transplantation reported that the median survival for all adult recipients was 7 years in bilateral lung recipients and 4.5 years in single lung recipients in the 2014 registry. While the survival rate has improved, the number of lung transplantations has grown steadily since 1985. [2] Although several recipients are off-pump during lung transplantation, 30 to 40% of recipients are supported by intracc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Materials and Methods

1) Study protocol
After obtaining the approval from the Institutional Review Board of Severance Hospital, we retrospectively investigated all patients undergoing lung transplantation from October 2012 to May 2015 in Severance Hospital. We included patients who had undergone one or two lung transplantations with intraoperative ECMO support by one surgeon. We excluded patients who underwent lung transplantation without intraoperative ECMO support, or combined with another surgery like coronary artery bypass surgery. Patients who had incomplete data associated with perioperative ECMO were also excluded. The patients were divided into two groups. The control group consisted of patients who were weaned from intraoperative ECMO at the end of surgery. The ECMO group consisted of patients for whom the intraoperative ECMO was prolonged to the immediate postoperative period for a few days, so that the transplanted lungs could recover.
2) Data collection
We collected perioperative data from electronic medical To achieve a target ACT of 180 to 200 seconds, ACT was measured every 30 minutes and additional heparin was administered. After implanted lung anastomosis and reperfusion, the duration of ECMO weaning was evaluated by the lung transplantation team. The ECMO flow was decreased by 500 to 1,000 mL/min for consideration of ECMO weaning. Finally, the decision to wean or maintain the intraoperative ECMO depended on the attending surgeon. When the Multiple logistic regression analysis using backwards step- Generally, we consider a p-value < 0.05 as significant, but due to the small size of this study, this was insufficient to identify a difference. Therefore, based on previous reports, we considered a p-value < 0.1 to be significant. [11] 
Results
Between October 2012 and May 2015, there were 64 patients who had undergone lung transplantation. Among these, 4 patients were excluded; 2 patients had undergone combined coronary artery bypass surgery, one patient had undergone simultaneous lung and liver transplantation and the other patient had insufficient data due to unknown preoperative ECMO insertion day and management. A total of 60 patients were enrolled in our study. Among the eligible patients, 34 were weaned from intraoperative ECMO (Control group) and 26 patients were included in the postoperative ECMO (ECMO group).
Patient's preoperative characteristics and comparison between the control group and the ECMO group are described in 23%, p = 0.036). The donors' characteristics are described in Table 2 . There were no significant variables among donors' characteristics.
Comparison of intraoperative variables between the control group and ECMO group are described in Table 3 were included in the multiple logistic regression models to identify an independent predictor for the use of postoperative ECMO, as shown in Table 4 (9) 3 (12) 0.528
Data are presented as mean ± standard deviation, median (25 inter quartile-75 interquartile) or n (%). ECMO: extracorporeal membrane oxygenation; CVA: cerebral vascular accident. *p < 0.1 between two groups. The incidence of PGD has been reported to vary from 5 to 30% of patients. [16, 17] PGD is associated with increased mechanical ventilation, longer stays in ICU, and increased probability of bronchiolitis obliterans syndrome. Also, PGD is the most important cause of early mortality and morbidity after lung transplantation. [12, 14] Therefore, many centers have studied the parameters for occurrence of PGD after lung transplantation. [7, 16] In the many studies over the use of postoperative ECMO at ICU, only a few reports have referred to the postoperative ECMO transfer from the operation room. In one report by Aigner et al [4] , the factors influencing the decision for The common complications include bleeding, renal failure, infection, stroke, arrhythmia and limb ischemia. In particular, the major complication was bleeding because ECMO needs heparin infusion to maintain an activated clotting time of 180 to 250 seconds. [18] In our study, wound drainage of postoperative 1 day in the ECMO group (2,920 ± 2,288 mL) was more than that in the Control group (1,563 ± 1,188 mL) ( Table 5 ). The incidence of bleeding that required reoperation was 35% (9/26) in the ECMO group versus 6% (2/34) in the Control group. Other complications aside from stroke occurred more in the ECMO group than in the control group, although some variables were not significantly different. These complications lead to prolonged mechanical ventilation and increased length of ICU stays. However, postoperative 30-day mortality showed no significant difference between the groups, despite the lower complications in the Control group. Based on previous reports that early initiation of ECMO for postoperative PGD leads to more optimal outcomes than delayed initiation of ECMO, [10, 13, 18] we assumed that the use of postoperative ECMO had a prophylactic effect for postoperative PGD, resulting in no significant difference in survival. The main weakness of this study was the paucity of eligible patients, so further work is needed to evaluate the adverse effects of postoperative ECMO on the long-term clinical outcomes such as 5-year survival rate.
When considering postoperative ECMO support after lung transplantation, VV ECMO was preferable to VA ECMO because VA ECMO had more risk of complications than VV ECMO. [19] In this study, postoperative VA ECMO was applied to only 4 patients among the 26 patients of ECMO group. The incidence of complications was higher in the VA ECMO group than the VV ECMO group, although only the differences in atrial fibrillation (100% in VA ECMO group vs. 22.7% in VV ECMO group, p = 0.008) and stroke (50% in VA ECMO group vs. 0% in VV ECMO group, p = 0.018)
were statistically significant. The expire rate was also significantly higher in the VA ECMO group than the VV ECMO group (75% vs. 22.7%, respectively, p = 0.072).
There were several limitations to our study. First, this study was performed at a single center and the sample size was relatively small, so the study was underpowered for several variables. Second, because this was a retrospective analysis, data collection and interpretation of data were limited. Each 
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